PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Show more

Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://pepgen.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

36.32M

52 Wk Range

$0.88 - $19.30

Previous Close

$1.11

Open

$1.12

Volume

392,409

Day Range

$1.05 - $1.12

Enterprise Value

-43.19M

Cash

97.78M

Avg Qtr Burn

-20.69M

Insider Ownership

0.27%

Institutional Own.

95.95%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PGN-EDODM1 Details Myotonic Dystrophy Type 1	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PGN-EDO51 Details Duchenne muscular dystrophy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.